SP
CMPX icon

Stonebrook Private’s Compass Therapeutics CMPX Stock Holding History

Stonebrook Private’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.8K Buy
10,365
+135
+1% +$779 0.01% 223
2025
Q4 		$54.9K Hold
10,230
– – 0.01% 208
2025
Q3 		$35.8K Sell
10,230
-366
-3% -$1.16K 0.01% 206
2025
Q2 		$27.6K Sell
10,596
-1,698
-14% -$3.5K 0.01% 195
2025
Q1 		$23.4K Buy
12,294
+1,006
+9% +$2.67K 0.01% 186
2024
Q4 		$16.4K Buy
+11,288
New +$18.7K ﹤0.01% 182

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Stonebrook Private's CMPX Position: Q1 2026 in Review

Stonebrook Private increased its Compass Therapeutics (CMPX) stake by 1.3% in Q1 2026, buying an estimated $779 and bringing the position to 10,365 shares worth $54.8K. The position accounts for 0.01% of the portfolio, ranked #223.

Stonebrook Private first reported a position in CMPX in Q4 2024 and has held it in 6 quarters since. The position peaked at $54.9K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Stonebrook Private held 10,365 shares of Compass Therapeutics worth $54.8K as of Q1 2026.
  • Stonebrook Private bought 135 Compass Therapeutics shares in Q1 2026, an estimated $779.
  • Compass Therapeutics made up 0.01% of Stonebrook Private's portfolio in Q1 2026, its #223 holding.
  • Stonebrook Private first reported a position in Compass Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Stonebrook Private's Compass Therapeutics position peaked at $54.9K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Stonebrook Private's 13F filing for Q1 2026, filed 11 May 2026.